Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01874145 (ClinicalTrials.gov)	June 2013	6/6/2013	Safety and Tolerability of Glatiramer Acetate	An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis	Drug: GA 20 mg/mL;Drug: GA 40 mg/mL	Teva Pharmaceutical Industries	NULL	Completed	18 Years	N/A	All	209	Phase 3	United States
2	NCT00202982 (ClinicalTrials.gov)	August 2003	12/9/2005	A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose	A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability and Safety of 40 mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients	Relapse-Remitting Multiple Sclerosis	Drug: glatiramer acetate 20 mg;Drug: glatiramer acetate 40 mg	Teva Pharmaceutical Industries	NULL	Completed	18 Years	50 Years	Both	90	Phase 2	United States